Australia's Island Pharmaceuticals jumps on acquisition of antiviral molecule
11/09/2024 02:19
** Shares of Island Pharmaceuticals ILA.AX rise as much as
9.1% to A$0.084, their highest since June 18
** Drug maker says it signed a binding letter of intent at
the cost of US$50k with BioCryst BCRX.O for the potential
acquisition of antiviral molecule, galidesivir
** Stock set for best day since Aug 7, if gains hold
** ILA down 1.7% YTD as of 0110 GMT
(Reporting by Adwitiya Srivastava in Bengaluru)
((Adwitiya.Srivastava@thomsonreuters.com))
Recent news on Island Pharmaceuticals
See all newsBrief: Island Pharmaceuticals Says Pivotal Marburg Data Secured For Galidesivir FDA Pathway
Brief: Island Pharmaceuticals Posts Prelim FY Loss Attributable Of A$9.8 Million
Australia's Island Pharmaceuticals rises as company boosts Galidesivir production
Brief: Island Pharmaceuticals Boosts Galidesivir Supply As Ebola Surges
Island Pharmaceuticals hits seven-month high on Galidesivir approval for Ebola epidemic